Silexion Therapeutics Corp(SLXN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

SLXN Silexion Therapeutics Corp

Trading 06-03 10:39:01 EDT

4.85

-0.14

-2.78%

High5.04	Low4.85	Vol73.40K
Open5.00	D1 Closing4.99	Amplitude3.81%
Mkt Cap2.03M	Tradable Cap1.96M	Total Shares419.00K
T/O363.48K	T/O Rate18.17%	Tradable Shares404.00K
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"SLXN","market":"US","secType":"STK","nameCN":"Silexion Therapeutics Corp","latestPrice":4.8513,"timestamp":1780497536211,"preClose":4.99,"halted":0,"volume":73399,"delay":0,"changeRate":-0.027795591182364736,"floatShares":404000,"shares":419000,"eps":-63.78105,"marketStatus":"Trading","change":-0.1387,"latestTime":"06-03 10:39:01 EDT","open":5,"high":5.04,"low":4.85,"amount":363481.463269,"amplitude":0.038076,"askPrice":4.9,"askSize":100,"bidPrice":4.85,"bidSize":72,"shortable":0,"etf":0,"ttmEps":-63.78105,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1780516800000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":4.99,"preHourTrading":{"tag":"盘前","latestPrice":4.9186,"preClose":4.99,"latestTime":"09:10 EDT","volume":922,"amount":4460.454366,"timestamp":1780492209733,"change":-0.0714,"changeRate":-0.014309,"amplitude":0.06004},"postHourTrading":{"tag":"盘后","latestPrice":4.98,"preClose":4.99,"latestTime":"19:50 EDT","volume":4314,"amount":21318.3143,"timestamp":1780444208110,"change":-0.01,"changeRate":-0.002004,"amplitude":0.032064},"volumeRatio":2.469464},"requestUrl":"/m/hq/s/SLXN/tweets","defaultTab":"tweets","newsList":[{"id":"2639621796","title":"Silexion Therapeutics executes 1-for-10 reverse share split","url":"https://stock-news.laohu8.com/highlight/detail?id=2639621796","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639621796?lang=en_us&edition=fundamental","pubTime":"2026-05-29 19:02","pubTimestamp":1780052564,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics set a 1-for-10 reverse share split, effective May 28, 2026, subject to board confirmation tied to Nasdaq bid-price compliance.Authorized share capital to be consolidated to US$796,500 divided into 5,900,000 ordinary shares with a par value of US$0.135.Issued ordinary shares to consolidate to 407,471 from 4,074,710, based on the April 7, 2026 share count.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silexion Therapeutics Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 29, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260529:nNDL4LfKm2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLXN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639124336","title":"Silexion Therapeutics Corp trading halted, news pending","url":"https://stock-news.laohu8.com/highlight/detail?id=2639124336","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639124336?lang=en_us&edition=fundamental","pubTime":"2026-05-29 07:50","pubTimestamp":1780012259,"startTime":"0","endTime":"0","summary":"19:50 EDT Silexion Therapeutics (SLXN) Corp trading halted, news pending Published first on TheFly – the ultimate source for real-time, market-movi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/silexion-therapeutics-corp-trading-halted-news-pending-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/silexion-therapeutics-corp-trading-halted-news-pending-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","SLXN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638514000","title":"Silexion Therapeutics announces 1-for-10 reverse share split","url":"https://stock-news.laohu8.com/highlight/detail?id=2638514000","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638514000?lang=en_us&edition=fundamental","pubTime":"2026-05-26 20:30","pubTimestamp":1779798645,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics will execute a 1-for-10 reverse share split, effective after the May 28 market close.Shares start trading on a split-adjusted basis on Nasdaq at the May 29 open under ticker SLXN.Each 10 ordinary shares will convert into 1 share; par value rises to $0.135 from $0.0135.No fractional shares will be issued; DTC participants entitled to fractions will receive rounded-up whole shares.Move targets Nasdaq’s $1 minimum bid requirement, aiming to support listing compliance and future equity financing flexibility.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260526:nNDLGXXDy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","SG9999014005.SGD","IE00B3QW5Z07.USD","BK4588","SG9999014021.USD","BK4112","BK4585","IE00BGHQF748.EUR","IE00B64PRP62.GBP","LU0314104364.USD","LU2210149790.SGD","IE00BKPKM429.USD","IE00BN0W2W23.USD","IE00BN0W2V16.EUR","NDAQ","SG9999014013.SGD","BK4139","LU2210150020.SGD","LU2095319765.USD","SLXN","IE00BN0W2T93.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638702514","title":"Silexion Therapeutics Announces 1-for-10 Reverse Share Split","url":"https://stock-news.laohu8.com/highlight/detail?id=2638702514","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638702514?lang=en_us&edition=fundamental","pubTime":"2026-05-26 20:30","pubTimestamp":1779798601,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260526:nTUA6VRR3K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SLXN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636849250","title":"Top Premarket Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2636849250","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636849250?lang=en_us&edition=fundamental","pubTime":"2026-05-20 19:14","pubTimestamp":1779275695,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics  shares were up 180% in Wednesday premarket trading after the company reported a narrower Q1 loss.GCL Global  stock was 94% higher, a day after the company said its publishing subsidiary, 4Divinity, received an additional $10 million investment from ADATA Technology.Micware  stock was up 84%, recovering from a 25% decline in the previous session.BiomX  shares were 40% higher after plunging 18% in the previous session.WORK Medical Technology  stock was up 24% following a 38% drop in Tuesday's trading session.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MWC","WOK","GCL","PHGE","BK4139","BK4198","BK4085","SLXN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636907303","title":"Silexion Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2636907303","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636907303?lang=en_us&edition=fundamental","pubTime":"2026-05-18 20:30","pubTimestamp":1779107401,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nTUA9ZRJ7D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SLXN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635605339","title":"Silexion net loss widens 58.8% to USD 2.73 million in Q1 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2635605339","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635605339?lang=en_us&edition=fundamental","pubTime":"2026-05-16 05:26","pubTimestamp":1778880384,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics posted a net loss of USD 2.73 million, widening 58.8% from the year-ago quarter.Operating loss widened to USD 2.75 million as operating expenses climbed to USD 2.75 million.Research and development expense more than doubled to USD 1.37 million, driven by higher subcontractor and consultant spending tied to toxicology studies, product development, and GMP manufacturing ahead of a planned human clinical trial expected in Q2 2026, subject to regulatory clearance.General and administrative expense rose 27.3% to USD 1.38 million on higher professional services costs related to operating as a public company.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silexion Therapeutics Corp. published the original content used to","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nNDL42H8r6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLXN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635030432","title":"Silexion Therapeutics sells unregistered warrants for 3990184 shares at $0.5 each","url":"https://stock-news.laohu8.com/highlight/detail?id=2635030432","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635030432?lang=en_us&edition=fundamental","pubTime":"2026-05-16 04:34","pubTimestamp":1778877294,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics signed warrant inducement deal covering 1,995,092 existing warrants, with holders agreeing to exercise for cash at reduced exercise price of $0.5 per share.Transaction expected to generate about USD 1 million gross proceeds, with closing targeted around May 18, 2026.As consideration, company will issue unregistered Series C and Series D warrants to buy up to 3,990,184 ordinary shares at $0.5 per share, subject to shareholder approval.H.C. Wainwright to act as placement agent, earning 7% cash fee plus 1% management fee, with placement agent warrants for up to 139,656 ordinary shares at $0.625 per share.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silexion Therapeutics Corp. published the original content used to","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nNDL6SsQYB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLXN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635842380","title":"Silexion Therapeutics says warrant exercises raise USD 1 million gross proceeds","url":"https://stock-news.laohu8.com/highlight/detail?id=2635842380","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635842380?lang=en_us&edition=fundamental","pubTime":"2026-05-15 20:27","pubTimestamp":1778848060,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics entered definitive agreements for immediate cash exercise of outstanding warrants covering 1,995,092 ordinary shares at reduced exercise price of USD 0.5 per share.Gross proceeds expected at about USD 1 million; closing expected on or about May 18, 2026.In exchange, investors to receive unregistered Series C warrants for 2,045,000 shares and unregistered Series D warrants for 1,945,184 shares, each exercisable at USD 0.5 per share subject to shareholder approval.Series C warrants set to expire five years from later of shareholder approval or effectiveness of resale registration statement; Series D warrants set to expire 24 months from same later date.Company agreed to file resale registration statement for shares underlying new warrants.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nNDL8ys9Lz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","IE00BN0W2V16.EUR","IE00BKPKM429.USD","LU2095319765.USD","IE00BGHQF748.EUR","BK4112","SG9999014021.USD","NDAQ","SG9999014039.USD","LU2210149790.SGD","SG9999014013.SGD","IE00BN0W2W23.USD","SLXN","LU2210150020.SGD","SG9999014005.SGD","BK4588","BK4139","LU0314104364.USD","BK4585","IE00BN0W2T93.GBP","IE00B3QW5Z07.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635273084","title":"Silexion Therapeutics Announces Exercise of Warrants for $1 Million Gross Proceeds","url":"https://stock-news.laohu8.com/highlight/detail?id=2635273084","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635273084?lang=en_us&edition=fundamental","pubTime":"2026-05-15 20:27","pubTimestamp":1778848020,"startTime":"0","endTime":"0","summary":"Grand Cayman, May  15, 2026  (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi) the","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/15/3295817/0/en/Silexion-Therapeutics-Announces-Exercise-of-Warrants-for-1-Million-Gross-Proceeds.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","SLXN","BK4007","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635748156","title":"Silexion Therapeutics Reports Positive Preliminary Immunotherapy Findings for Sil204 in Kras-Driven Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2635748156","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635748156?lang=en_us&edition=fundamental","pubTime":"2026-05-14 21:27","pubTimestamp":1778765220,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nTUA21NVWW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SLXN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635748295","title":"Silexion Therapeutics Reports Positive Preliminary Immunotherapy Findings for SIL204 in KRAS-Driven Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2635748295","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635748295?lang=en_us&edition=fundamental","pubTime":"2026-05-14 21:27","pubTimestamp":1778765220,"startTime":"0","endTime":"0","summary":"Preliminary results from a preclinical study demonstrated statistically significant increase in MHC-I expression following SIL204 treatment in human pancreatic and non-small cell lung cancer cells har","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/14/3295074/0/en/Silexion-Therapeutics-Reports-Positive-Preliminary-Immunotherapy-Findings-for-SIL204-in-KRAS-Driven-Pancreatic-Cancer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLXN","BK4539","LENZ","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635731966","title":"Silexion Therapeutics initiates GMP clinical batch manufacturing of SIL204","url":"https://stock-news.laohu8.com/highlight/detail?id=2635731966","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635731966?lang=en_us&edition=fundamental","pubTime":"2026-05-14 00:35","pubTimestamp":1778690151,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics (SLXN) announced the initiation of good manufacturing practice, or GMP, clinical batch manufacturing of SIL204, the company’s...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/silexion-therapeutics-initiates-gmp-clinical-batch-manufacturing-of-sil204-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/silexion-therapeutics-initiates-gmp-clinical-batch-manufacturing-of-sil204-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4539","SLXN","BK4007","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635610784","title":"Silexion initiates Phase 2/3 SIL204 trial in locally advanced pancreatic cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2635610784","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635610784?lang=en_us&edition=fundamental","pubTime":"2026-05-13 20:05","pubTimestamp":1778673922,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics began GMP manufacturing of clinical supply for SIL204, positioning next-generation KRAS-targeting siRNA candidate for planned Phase 2/3 trial in locally advanced pancreatic cancer.No trial results have been presented; upcoming study is intended to generate safety and efficacy readouts, starting with safety run-in before moving to randomized stage.Manufactured batches are intended to support first patient dosing, reducing a key execution risk ahead of trial start.Tel Aviv Sourasky Medical Center ethics committee cleared site participation, strengthening near-term clinical start-up prospects alongside ongoing regulatory work in Israel and Germany.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nNDL2DjR88:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","SG9999014005.SGD","LU2210149790.SGD","IE00BN0W2T93.GBP","IE00BN0W2W23.USD","IE00BGHQF748.EUR","BK4585","LU0314104364.USD","LU2210150020.SGD","BK4112","NDAQ","IE00B3QW5Z07.USD","IE00BN0W2V16.EUR","BK4588","BK4139","SG9999014013.SGD","SLXN","IE00B64PRP62.GBP","SG9999014021.USD","SG9999014039.USD","LU2095319765.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635848867","title":"Silexion Therapeutics Announces Initiation of Gmp Clinical Supply Manufacturing of Sil204 With Leading Global CDMO, and New Approval of Phase 2/3 Trial From Tel Aviv Sourasky Medical Center","url":"https://stock-news.laohu8.com/highlight/detail?id=2635848867","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635848867?lang=en_us&edition=fundamental","pubTime":"2026-05-13 20:00","pubTimestamp":1778673600,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nTUAP8PPD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SLXN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631546617","title":"Maxim Group Sticks to Their Buy Rating for Silexion Therapeutics (SLXN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2631546617","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631546617?lang=en_us&edition=fundamental","pubTime":"2026-04-29 23:17","pubTimestamp":1777475844,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Naz Rahman from Maxim Group reiterated a Buy rating on Silexion Therapeutics, with a price target of $6.00. Accordi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/maxim-group-sticks-to-their-buy-rating-for-silexion-therapeutics-slxn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/maxim-group-sticks-to-their-buy-rating-for-silexion-therapeutics-slxn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SLXN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630858305","title":"Silexion Therapeutics submits SIL204 clinical trial application to Germany","url":"https://stock-news.laohu8.com/highlight/detail?id=2630858305","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630858305?lang=en_us&edition=fundamental","pubTime":"2026-04-28 22:13","pubTimestamp":1777385628,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics (SLXN) announced the recent successful submission of a clinical trial application, or CTA, to Germany for its planned Phase 2...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/silexion-therapeutics-submits-sil204-clinical-trial-application-to-germany-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/silexion-therapeutics-submits-sil204-clinical-trial-application-to-germany-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","SLXN","BK4139","BK4539","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630650302","title":"Silexion submits Germany trial application for SIL204 pancreatic cancer study","url":"https://stock-news.laohu8.com/highlight/detail?id=2630650302","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630650302?lang=en_us&edition=fundamental","pubTime":"2026-04-28 20:45","pubTimestamp":1777380338,"startTime":"0","endTime":"0","summary":"Silexion submitted Phase 2/3 clinical trial application to Germany BfArM via EU CTIS for SIL204 in KRAS-driven locally advanced pancreatic cancer.Germany will act as reporting member state for EU-wide scientific assessment under EU Clinical Trials Regulation.Company still targets Phase 2/3 trial start in Q2 2026.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260428:nNDL22tCDL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","BK4139","LU0314104364.USD","IE00BN0W2W23.USD","LU2210150020.SGD","IE00BKPKM429.USD","LU2095319765.USD","SG9999014013.SGD","IE00BN0W2V16.EUR","BK4588","LU2210149790.SGD","SLXN","BK4585","IE00B3QW5Z07.USD","SG9999014005.SGD","SG9999014021.USD","IE00BGHQF748.EUR","IE00BN0W2T93.GBP","NDAQ","BK4112","SG9999014039.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630130263","title":"Silexion Therapeutics Announces Successful Submission of Phase 2/3 Clinical Trial Application to Germany’s Bfarm for Sil204 in Kras-Driven Locally Advanced Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2630130263","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630130263?lang=en_us&edition=fundamental","pubTime":"2026-04-28 20:45","pubTimestamp":1777380300,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260428:nTUA8120Y5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SLXN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622049150","title":"Silexion Therapeutics removes Ilan Levin from board; change effective immediately","url":"https://stock-news.laohu8.com/highlight/detail?id=2622049150","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622049150?lang=en_us&edition=fundamental","pubTime":"2026-03-26 04:07","pubTimestamp":1774469253,"startTime":"0","endTime":"0","summary":"The board approved the removal through a unanimous written determination by the other directors.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silexion Therapeutics Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 25, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nNDL6XVlWt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLXN"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.silexion.com","stockEarnings":[{"period":"1week","weight":0.1624},{"period":"1month","weight":-0.166},{"period":"3month","weight":-0.703},{"period":"6month","weight":-0.8424},{"period":"1year","weight":-0.9653},{"period":"ytd","weight":-0.7401}],"compareEarnings":[{"period":"1week","weight":0.012},{"period":"1month","weight":0.054},{"period":"3month","weight":0.1087},{"period":"6month","weight":0.1098},{"period":"1year","weight":0.2815},{"period":"ytd","weight":0.1139}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Moringa Acquisition Corp does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses. The company focuses on pursuing opportunities in technology-based businesses or industries in Israel. Moringa Acquisition Corp was incorporated in 2020 and is based in New York, New York.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.016335},{"month":2,"riseRate":0.6,"avgChangeRate":-0.095221},{"month":3,"riseRate":0.8,"avgChangeRate":-0.040641},{"month":4,"riseRate":0.6,"avgChangeRate":-0.119987},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.024382},{"month":6,"riseRate":0.5,"avgChangeRate":-0.026866},{"month":7,"riseRate":1,"avgChangeRate":0.055675},{"month":8,"riseRate":0.4,"avgChangeRate":-0.277749},{"month":9,"riseRate":0.6,"avgChangeRate":-0.230878},{"month":10,"riseRate":0.4,"avgChangeRate":-0.091257},{"month":11,"riseRate":0.4,"avgChangeRate":-0.018649},{"month":12,"riseRate":0.2,"avgChangeRate":-0.12005}],"exchange":"NASDAQ","name":"Silexion Therapeutics Corp","nameEN":"Silexion Therapeutics Corp"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Silexion Therapeutics Corp(SLXN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Silexion Therapeutics Corp(SLXN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Silexion Therapeutics Corp,SLXN,Silexion Therapeutics Corp股票,Silexion Therapeutics Corp股票老虎,Silexion Therapeutics Corp股票老虎国际,Silexion Therapeutics Corp行情,Silexion Therapeutics Corp股票行情,Silexion Therapeutics Corp股价,Silexion Therapeutics Corp股市,Silexion Therapeutics Corp股票价格,Silexion Therapeutics Corp股票交易,Silexion Therapeutics Corp股票购买,Silexion Therapeutics Corp股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Silexion Therapeutics Corp(SLXN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Silexion Therapeutics Corp(SLXN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction